Compare Novo Nordisk A/S (NVO) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Prologis Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Prologis Inc trades at $151.05 (market cap $137.50B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | PLD | |
|---|---|---|
Market Cap | $220.53B | $137.50B |
Sector | Health | Real Estate |
52-Week High | $71.70 | $149.96 |
52-Week Low | $35.29 | $104.08 |
Enterprise Value | $239.49B | $172.18B |
Dividend Yield | 3.63% | 2.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
